Hans Verbaan (Former)
11 – 20 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
(
- Contribution to journal › Article
- 2011
-
Mark
IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection
(
- Contribution to journal › Article
-
Mark
The clinical importance in differentiating portal from mesenteric venous thrombosis.
(
- Contribution to journal › Article
- 2010
-
Mark
Il28B Genetic Variation And Treatment Response In Patients With Hcv Genotype 3 Infection
2010) 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 52(4). p.898-898(
- Contribution to journal › Published meeting abstract
-
Mark
Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study
(
- Contribution to journal › Article
-
Mark
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials.
(
- Contribution to journal › Article
-
Mark
Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis.
(
- Contribution to journal › Article
- 2009
-
Mark
Low-To-Moderate Alcohol Consumption has no Impact on Antiviral Response to Combination Therapy In Hcv Patients with Genotype 2 or 3
2009) 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases In Hepatology 50(4). p.819-819(
- Contribution to journal › Published meeting abstract
-
Mark
Health-related quality of life in patients with different stages of liver disease induced by hepatitis C
(
- Contribution to journal › Article
-
Mark
RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B
2009) 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver In Journal of Hepatology 50(Suppl 1). p.232-232(
- Contribution to journal › Published meeting abstract